Rate My Professor Simon Dimmitt

Simon Dimmitt serves as Conjoint Professor in the School of Medicine and Public Health at the University of Newcastle and Clinical Professor of Medicine at the University of Western Australia. A qualified MBBS, BMedSc (Hons), FRACP, FCSANZ, he practices as a Consultant Physician in General and Cardiovascular Medicine, with prior professional experience in the United Kingdom and New Zealand. At Royal Perth Hospital, he contributed to establishing Western Australia's inaugural Stroke Unit and Lipid Clinic. He developed the University of Western Australia's initial courses in Medicine for Dentistry and Medicine for Podiatry, authoring associated postgraduate textbooks published by UWA Press, including Rational Clinical Examination.

For more than two decades, Professor Dimmitt has acted as a National Examiner and Hospital Site Physician Training Accreditor for the Royal Australasian College of Physicians and currently chairs the National Human Research Ethics Committee of St John of God Health Care. His scholarly output encompasses nearly 100 publications addressing hypertension, hyperlipidaemia, cardiology, endocrinology, and clinical pharmacology, with a particular emphasis on dose optimization informed by the effective dose 50 (ED50) to maximize efficacy while minimizing toxicity. Notable contributions include When less is more – efficacy with less toxicity at the ED50 (British Journal of Clinical Pharmacology, 2017), The rationale of dose–response curves in selecting cancer drug dosing (British Journal of Clinical Pharmacology, 2019), Optimising low-dose methotrexate for rheumatoid arthritis—A review (British Journal of Clinical Pharmacology, 2019), Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50 (British Journal of Clinical Pharmacology, 2024), and observations on intensive lipid-lowering therapy (Medical Journal of Australia, 2019). He promotes lower doses in preventive cardiology, highlighting improved chronic disease outcomes and reduced harms from excessive beta-blocker dosing. In 2025, he was elected a Fellow of the British Pharmacological Society.